Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions

Kidney CancerRCCRenal Cell Carcinoma

Interventions

DRUG

Vorolanib

stage Ⅰ：Vorolanib 200mg QD stage Ⅱ：Vorolanib RP2D QD

DRUG

cadonilimab

stageⅠ：cadonilimab 10mg/kg Q3W stageⅡ：cadonilimab 10mg/kg Q3W

All Listed Sponsors

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER